Pradaxa Lawsuit | Dabigatran Lawsuit | Recall, Litigation, Lawsuits, Lawyer, Attorney
Pradaxa Lawsuit | Dabigatran Lawsuit | Pradaxa Injury, Injuries | Recall, Litigation, Lawsuits, Lawyer, Attorney | Pradaxa Side Effects : Gastrointestinal Bleeding, GI Bleed, Hemorrhaging, Brain Hemorrhaging, Death, Bleeding Death, Hemorrhaging Death | Pradaxa Lawsuit Commercial,
Pradaxa Lawsuits Filed, Pradaxa Class Action Lawsuits
The blood thinner Pradaxa (dabigatran etexilate mesylate) has been associated with severe, and sometimes deadly, instances of internal bleeding and hemorrhaging, especially in elderly patients and those with kidney disorders. Boehringer Ingelheim, the maker of Pradaxa, has marketed the drug as an improvement over warfarin, a decades-old blood thinner sold under the brand name Coumadin. Unlike warfarin, however, there is no known antidote to Pradaxa bleeding. As a result, even minor trauma can cause Pradaxa patients to suffer uncontrollable, life-threatening internal hemorrhaging. In November 2010, Boehringer Ingelheim acknowledged that it had received reports of 260 deaths associated with Pradaxa bleeding.
The leading law firm of Alonso Krangle LLP is currently investigating potential lawsuit claims on behalf of individuals who suffered serious incidents of Pradaxa bleeding or hemorrhaging. Many Pradaxa victims or their loved ones have already filed Pradaxa bleeding lawsuits alleging Boehringer Ingelheim failed to adequately warn of serious Pradaxa side effects, including
- Cerebral Hemorrhage, or Brain Bleeds
- Gastrointestinal Bleeding, or Stomach Bleeds
- Rectal Bleeding
- Kidney Bleeding
- Heart Attack
- Death from Serious Internal Bleeding
Alonso Krangle LLP is offering free lawsuit evaluations to all Pradaxa bleeding victims, or their survivors. If you or someone you love suffered dangerous internal bleeding or hemorrhaging while taking Pradaxa, please contact the defective drug lawyers at Alonso Krangle LLP today to learn more about the legal options available to you.
Pradaxa Bleeding Lawsuits
Pradaxa was approved by the U.S. Food Drug Administration (FDA) in October 2010 to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Pradaxa was the first of a new class of blood thinners called direct thrombin inhibitor anticoagulants. These drugs are supposed to offer advantages over warfarin, which requires that patients submit to frequent blood draws to monitor its blood thinning effects. As is the case with all blood thinners, internal bleeding is a potential Pradaxa side effect. However, while warfarin bleeding can be stopped with the administration of vitamin K, there is no readily available antidote to Pradaxa bleeding. The only known way to stop Pradaxa bleeding is emergency dialysis, something that many doctors say is impractical, as it may not work quickly enough to stop a dangerous episode of Pradaxa bleeding.
In December 2011, the FDA announced it had launched a safety review of Pradaxa to investigate reports of internal bleeding and internal hemorrhaging among Pradaxa patients. The FDA announcement followed Boehringer Ingelheim’s acknowledgement of 260 Pradaxa-related deaths, as well as investigations into Pradaxa bleeding deaths in Japan and Europe. Since then, the Institute for Safe Medication Practices has reported that Pradaxa accounted for over 3000 serious adverse event reports made to the FDA in 2011, including over 500 patient deaths.
The FDA has warned physicians not to prescribe Pradaxa to patients with poor kidney function. In these patients, Pradaxa may build up in the bloodstream to unsafe levels, inhibiting the body’s ability to cause blood to clot should hemorrhaging or bleeding occur. In Europe, doctors have been advised to test patients’ kidney functions to reduce chances of bleeding complications prior to initiating a regimen of Pradaxa. In May 2012, a case study published in the Journal of Neurosurgery raised concerns that the elderly may be especially vulnerable to Pradaxa bleeding. The article detailed the death of an 83-year-old Pradaxa patient from uncontrollable brain hemorrhaging following a minor fall. It has been reported that the elderly have a higher risk of suffering a severe Pradaxa bleeding episode because they are more likely to suffer balance problems that can cause such falls.
Legal Help for Victims of Pradaxa Bleeding Side Effects
If you or someone you love experienced serious internal bleeding or hemorrhaging while taking Pradaxa, the defective drug lawyers at Alonso Krangle LLP would like to talk with you. For a free lawsuit evaluation, please fill out our online form, or call us.